(Q44804231)

6 December 2017

1 reference

title

Aggressive multiple sclerosis. Definition and specific therapeutic indication (English)

1 reference

6 December 2017

main subject

therapeutic indication

1 reference

Gilles Edan

1

1 reference

6 December 2017

language of work or name

French

0 references

publication date

1 February 2004

1 reference

6 December 2017

0 references

33

1 reference

6 December 2017

issue

3

1 reference

6 December 2017

page(s)

187-91; discussion 192

1 reference

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2804%2998520-X

7 January 2021

Suppression of experimental allergic encephalomyelitis by mitoxantrone.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2804%2998520-X

7 January 2021

Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2804%2998520-X

7 January 2021

Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2804%2998520-X

7 January 2021

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2804%2998520-X

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2804%2998520-X

7 January 2021

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2804%2998520-X

7 January 2021

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2804%2998520-X

7 January 2021

Mitoxantrone in progressive multiple sclerosis: when and how to treat?

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2804%2998520-X

7 January 2021

Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2804%2998520-X

7 January 2021

10.1016/S0755-4982(04)98520-X

Identifiers

DOI

1 reference

6 December 2017

1 reference